Skip to main content
Journal cover image

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Publication ,  Journal Article
Rider, LG; Aggarwal, R; Pistorio, A; Bayat, N; Erman, B; Feldman, BM; Huber, AM; Cimaz, R; Cuttica, RJ; de Oliveira, SK; Lindsley, CB ...
Published in: Arthritis Rheumatol
May 2017

OBJECTIVE: To develop response criteria for juvenile dermatomyositis (DM). METHODS: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. RESULTS: Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute percent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P = 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006). CONCLUSION: The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

May 2017

Volume

69

Issue

5

Start / End Page

911 / 923

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Surveys and Questionnaires
  • Societies, Medical
  • Rituximab
  • Rheumatology
  • Reproducibility of Results
  • Prednisone
  • Patient Reported Outcome Measures
  • Outcome Assessment, Health Care
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rider, L. G., Aggarwal, R., Pistorio, A., Bayat, N., Erman, B., Feldman, B. M., … International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation, . (2017). 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol, 69(5), 911–923. https://doi.org/10.1002/art.40060
Rider, Lisa G., Rohit Aggarwal, Angela Pistorio, Nastaran Bayat, Brian Erman, Brian M. Feldman, Adam M. Huber, et al. “2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.Arthritis Rheumatol 69, no. 5 (May 2017): 911–23. https://doi.org/10.1002/art.40060.
Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N, International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017 May;69(5):911–923.
Journal cover image

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

May 2017

Volume

69

Issue

5

Start / End Page

911 / 923

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Surveys and Questionnaires
  • Societies, Medical
  • Rituximab
  • Rheumatology
  • Reproducibility of Results
  • Prednisone
  • Patient Reported Outcome Measures
  • Outcome Assessment, Health Care